ERNA
Ernexa Therapeutics Inc.
There isn't enough reported data to score ERNA yet.
ERNA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ERNA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
ERNA PE Valuation
ERNA has no meaningful PE right now: it lost money over the past year.
ERNA Forward outlook
There aren't enough analyst estimates for ERNA to show an outlook.
ERNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2022 | -$4,308.75 | +$13,541.25 |
| Q2 2022 | -$16,125.00 | -$3,525.00 |
| Q1 2022 | -$17,475.00 | +$3,675.00 |
| Q4 2021 | -$21,000.00 | +$1,650.00 |
| Q3 2021 | -$17,850.00 | +$13,200.00 |
| Q2 2021 | -$12,600.00 | +$12,750.00 |
| Q1 2021 | -$21,150.00 | -$5,700.00 |
| Q4 2020 | -$22,650.00 | -$11,850.00 |
ERNA lost $3,116.25 per share over the past year, a smaller loss than the year before, but its loss has widened in each of the last three quarters.
ERNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $1K | -94% |
| Q3 2024 | $487K | +855% |
| Q4 2020 | $1.2M | -77% |
ERNA's revenue has slid since its 2019 peak: $1,000 last quarter, down 94% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -269700% | -235788 points |
| Q3 2024 | -464% | +10330 points |
| Q2 2024 | -10491% | N/A |
| Q1 2024 | -12313% | N/A |
| Q4 2023 | -33912% | N/A |
| Q3 2023 | -10794% | N/A |
| Q4 2020 | -63% | -39 points |
| Q3 2020 | -96% | N/A |
ERNA's operating margin was −269700% last quarter, down 235788 points from the same quarter a year ago, near the bottom of its range since 2019.
ERNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$1.2M | +$2.4M |
| Q4 2024 | -$3.5M | +$1.1M |
| Q3 2024 | -$6.3M | -$478K |
| Q2 2024 | -$2.5M | +$1.4M |
| Q1 2024 | -$3.8M | +$2.2M |
| Q4 2023 | -$4.7M | +$776K |
| Q3 2023 | -$5.8M | +$333K |
| Q2 2023 | -$3.9M | +$308K |
ERNA has burned cash in almost every quarter: −$11M over the past year, against −$16M the year before.
ERNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | 0% | -- |
| 3 years | +7298% | +14.2K shares |
ERNA has 14,427 diluted shares, about the same as a year ago.
ERNA Net Leverage
ERNA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ERNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.0 | Oversold |
| Stochastic | 2.9 | Oversold |
ERNA's weekly RSI is 30 (oversold) and its Stochastic is 3 (oversold).
ERNA PE vs Healthcare Sector
ERNA has no meaningful PE right now: it lost money over the past year.
ERNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.33 | 23% below |
| 20 week MA | $3.74 | 52% below |
| 50 week MA | $10.2 | 82% below |
| 100 week MA | $40.6 | 96% below |
| 200 week MA | $416.1 | 100% below |
ERNA is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
ERNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33,600.0 | $32,250.0 | -4% |
| 2021 | $32,250.0 | $37,425.0 | +16% |
| 2022 | $37,425.0 | $1,286.3 | -97% |
| 2023 | $1,286.3 | $675.0 | -48% |
| 2024 | $675.0 | $95.0 | -86% |
| 2025 | $95.0 | $30.3 | -68% |
| 2026 YTD | $30.3 | $1.79 | -94% |
ERNA has finished four years in a row lower, and it's down 94% so far in 2026.